Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.

Kate C ChiangJohn George RizkDeanna J NelsonLakshmanan KrishnamurtiSelvakumar SubbianJohn D ImigImran KhanSrinivasa T ReddyAjay Gupta

Published in: Expert opinion on therapeutic targets (2022)

Ramatroban, a dual blocker of TP and DP2 receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, as well as preliminary evidence for rapid relief from dyspnea and hypoxemia in COVID-19 pneumonia. Ramatroban merits investigation as a promising antithrombotic and immunomodulatory agent for chemoprophylaxis and treatment.

Keyphrases

coronavirus disease
sars cov
cardiovascular disease
intensive care unit
type diabetes
atrial fibrillation
septic shock
replacement therapy